歌礼制药(01672.HK)ASC47-103研究完成首批受试者给药

阿斯达克财经
20 May

歌礼制药(01672.HK) 公布,旨在评估超长效皮下注射ASC47单次给药联合司美格鲁肽在不伴有2型糖尿病的肥胖受试者中的安全性及初步疗效的随机、双盲、安慰剂对照研究(ASC47-103研究)已完成首批受试者给药。

ASC47-103研究在美国开展,共设3个队列,受试者接受ASC47单剂量递增(10毫克、30毫克和60毫克)或注射等量(volume-matched)安慰剂。研究的顶线数据预计将于今年第四季度公布。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-20 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10